ArticleMethods in molecular biology (Clifton, N.J.)2024
In Vivo Bioluminescence and Fluorescence Imaging: Optical Tool for Cancer Research.
Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The ESRP1 promoter reporter can function as an in vivo sensor of DNA methyltransferase inhibition.BMC biotechnology · 2025Article
- Comparison of the efficacy of FITC-conjugated dextran, PEG, and HA as intraoperative navigation materials in pancreatic cancer.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vivo whole-body imaging, using optical tools based on bioluminescence and fluorescence detection, offers tremendous opportunities to specifically determine the spatiotemporal resolution of cancer cells within the tested animals. This enables the study of many aspects of cancer biology, including cell proliferation, trafficking, and invasions. The antitumor therapeutic properties of various tested compounds (e.g., CD19 CAR-T cells, used for cancer immunotherapy) can be monitored within the same animal at different time points, significantly reducing the number of animals used in the study as indicated in this method.
Indexed as
Identifiers
38236541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.